Dr. Keith Conners, who recently passed away at age 84, was among the first child psychologists to identify what is now known as “attention deficit hyperactivity disorder,” or ADHD. Best known for establishing the first standards for the diagnosis and treatment of ADHD, Conners reportedly had regrets toward the end of his life over how freely children today are labeled with the condition.
Last October, the FDA was prepared to remove two generic versions of the ADHD drug Concerta (methylphenidate hydrochloride) from the market, citing the medication failed to perform adequately. Now, the federal regulatory agency is giving drugmakers Lannett and Mallinckrodt Pharmaceuticals an additional month to demonstrate why it should be allowed to remain.
Like so many other Big Pharma players, Janssen pulls out all the stops in its marketing efforts when it comes to Concerta. One of the big selling points of Concerta and other ADHD medication is it helps kids in getting better grades in school and completing their homework assignments. But does it, really?
Concerta, a pharmaceutical manufactured and marketed by Johnson & Johnson subsidiary Janssen Pharmaceutica, is one of the latest in a line of prescription drugs that have been found to have serious, and even fatal side effects that the company allegedly knew about and of which they failed to inform the public. In a society and at a time when people are looking for “quick fixes” for perceived disorders, such stories are becoming increasingly common.